Free Trial
→ Why Iran May Only Be the First Move (From Behind the Markets) (Ad)tc pixel
NASDAQ:MIST

Milestone Pharmaceuticals Q3 2026 Earnings Date & Estimates

Milestone Pharmaceuticals logo
$0.69 -0.05 (-6.50%)
As of 02:16 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Milestone Pharmaceuticals is estimated to report Q3 2026 earnings on Friday, November 13, 2026, before market opens. The conference call is scheduled for 8:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Milestone Pharmaceuticals in Q3 2026

Milestone Pharmaceuticals is expected to post earnings of -$0.20 per share on revenue of $1 million. In the same quarter a year earlier Milestone Pharmaceuticals reported -$0.12 per share. Milestone Pharmaceuticals last reported on August 12, 2026, posting -$0.21 per share and missing the -$0.1950 consensus estimate. Milestone Pharmaceuticals has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.20
Expected Revenue
$1 million
Prior-Year EPS
-$0.12

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.21 (Missed by -$0.0150)
Last Quarter Revenue
$559 thousand
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

Milestone Pharmaceuticals Q3 2026 Earnings FAQ

Milestone Pharmaceuticals (NASDAQ:MIST) is estimated to report Q3 2026 earnings on Friday, November 13, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Milestone Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Milestone Pharmaceuticals to post earnings of -$0.20 per share for Q3 2026.

The consensus revenue estimate for Milestone Pharmaceuticals is $1 million for Q3 2026.

Milestone Pharmaceuticals Earnings Headlines

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Stock Now Rated "Moderate Buy" by Wall Street Brokerages
November 10 at 2:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31188884
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/04/3394973/0/en/milestone-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
Executive Order 14241 Unleashes Trump’s New Dollar
A landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December. The agenda at the upcoming G20 Summit in Miami has shifted, and new research points to a major monetary announcement from President Trump. A new documentary breaks down what this shift could mean for savings, investments, and the assets tied to it.tc pixel
November 10 at 1:00 AM  |  Porter & Company (Ad)
Milestone Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 13, 2026
November 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/03/3394126/0/en/milestone-pharmaceuticals-to-announce-third-quarter-2026-financial-results-on-november-13-2026.html
New Data Presented at AHA Scientific Sessions 2026 Demonstrate That CARDAMYST® (etripamil) Nasal Spray Converted Recurrent PSVT to Normal Heart Rhythm in Patients with Prior ...
November 2, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/new-data-presented-at-aha-scientific-sessions-2026-demonstrate-that-cardamyst-etripamil-nasal-spray-converted-recurrent-psvt-to-normal-heart-rhythm-in-patients-with-prior-catheter-ablation-1036700268
New Data Presented at AHA Scientific Sessions 2026 Demonstrate That CARDAMYST® (etripamil) Nasal Spray Converted Recurrent PSVT to Normal Heart Rhythm in Patients with Prior Catheter Ablation
November 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/02/3393096/0/en/new-data-presented-at-aha-scientific-sessions-2026-demonstrate-that-cardamyst-etripamil-nasal-spray-converted-recurrent-psvt-to-normal-heart-rhythm-in-patients-with-prior-catheter-.html
See More Milestone Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Milestone Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Milestone Pharmaceuticals and other key companies, straight to your email.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals (NASDAQ:MIST) is a biopharmaceutical company focused on developing and commercializing therapies for cardiovascular conditions. The company’s research is centered on treatments designed to provide rapid, patient-administered relief for episodic cardiovascular disorders.

Milestone’s lead product is etripamil, a short-acting calcium channel blocker formulated as a nasal spray. The therapy has been developed primarily for the treatment of paroxysmal supraventricular tachycardia, or PSVT, a condition characterized by episodes of abnormally rapid heart rate. By enabling administration outside of a hospital or clinical setting, etripamil is intended to give patients and healthcare providers an alternative to emergency-based treatment for certain acute episodes.

Milestone Pharmaceuticals was founded in Canada and conducts its development activities in North America. The company is headquartered in Montreal, Quebec, and its shares trade on the Nasdaq Capital Market under the symbol MIST. Joseph Oliveto serves as the company’s president and chief executive officer.

View Milestone Pharmaceuticals Profile
Earnings Tools